background cardiovascular disease is the leading cause of mortality among adults with type 2 diabetesthe thiazolidinediones including rosiglitazone are approved for the treatment of type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular diseaseobjectives to ascertain the cardiovascular skeletal and hematologic safety profile of rosiglitazonemethods synthesis of evidence from recent trials systematic reviews metaanalysis regulatory documents and clinical trials registries of manufacturersconclusion rosiglitazone increases the risk of heart failure myocardial infarction and fractures in women with type 2 diabetes